ClinicalTrials.gg
CompletedNCT04893811Updated Oct 16, 2024Results posted

Trial to Describe the Safety, Tolerability, and Immunogenicity of Trumenba When Administered to Immunocompromised Participants ≥10 Years of Age

A Phase 4 interventional study of Trumenba in Meningococcal Vaccine, sponsored by Pfizer. Completed at 14 sites in 3 countries. Open to participants aged 10 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-16.

Sponsored by Pfizer · Phase 4, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
53
Allocation
Not applicable
Ages
10 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 32 studies in Anemia, Sickle Cell by Pfizer — 1 open to participants now, 1 under way, 1 of them phase 3. Anemia, Sickle Cell · Pfizer.

Enrollment
13th of 27
53 · median 52
Started
2021
with 4 others
Phase 4
3 of 32
none open now
Registered
16th of 32
by date

Among the 32 studies in Anemia, Sickle Cell by Pfizer, this one is the 13th largest by enrollment of the 27 interventional ones that give a count, is one of 5 that started in 2021, is one of 3 in phase 4, and was the 16th registered.

Anemia, Sickle Cell

1,134 studies on the registry are indexed under Anemia, Sickle Cell; 238 are open to participants now.

Browse Anemia, Sickle Cell studies →

Open to participants now

1 of the 32 studies in Anemia, Sickle Cell by Pfizer is open now, in 7 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.

This study: 10 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Anemia, Sickle Cell by Pfizer, or all of them as a file.
02

Study summary

The aim of this study is to evaluate the safety, tolerability, and immunogenicity of 2 doses of Trumenba® (on a 0- and 6-month schedule) in immunocompromised participants by functionally assessing antibody production in asplenic and complement-deficient individuals ≥10 years of age.

03

Conditions studied

  • Meningococcal Vaccine

Browse trials for

Keywords

  • Meningococcal Vaccine
  • Meningitis Vaccine
  • Asplenia
  • Sickle cell anemia
  • Complement deficiencies
04

Who can participate

Ages eligible
10 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female participants ≥10 years of age at the time of consent.
  • Participants with an increased risk for meningococcal disease due to anatomic asplenia or functional asplenia (eg, sickle cell anemia) or complement deficiencies.
  • Negative urine pregnancy test for all female participants.

Exclusion criteria

Exclusion Criteria:

  • Previous vaccination with any meningococcal serogroup B vaccine.
  • Participants who are receiving any allergen immunotherapy with a nonlicensed product or receiving allergen immunotherapy with a licensed product and are not on stable maintenance doses.
  • History of microbiologically proven disease caused by N meningitidis or Neisseria gonorrhoeae.
  • Significant neurological disorder or history of seizure (excluding simple febrile seizure).
  • Any neuroinflammatory or condition, including, but not limited to, transverse myelitis, uveitis, optic neuritis, and multiple sclerosis.
  • Any confirmed or suspected infection.
  • Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
  • Receipt of immunoglobulin infusion or injection during the 42 days preceding enrollment.
  • Current chronic use of systemic antibiotics.
  • Previous receipt or current use of complement inhibitors (eg, eculizumab, ravulizumab).
  • Participation in other studies involving drug(s) within 28 days prior to study entry and/or during study participation.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
53 participants (actual)

Study arms

  • Experimental
    Single Arm

    Bivalent recombinant lipoprotein 2086 vaccine

    Biological: Trumenba

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer => Lower Limit of Quantitation (LLOQ) for Each of the 4 Primary Neisseria Meningitidis Serogroup B (MnB) Test Strains at Baseline

    Four primary MnB strains were PMB80 (A22), PMB2001 (A56), PMB2948 (B24) and PMB2707 (B44). The percentage of participants who achieved an hSBA titer PMB80 (A22) more than or equal to (=\>)1:16, and hSBA titer PMB2001 (A56), PMB2001 (B24), and PMB2707 (B44) =\>1:8 are reported. Evaluable immunogenicity population (EIP) included all participants who were eligible through 1 month after Vaccination 2, received the study vaccination at Visit 1 and Visit 3 as planned, had blood drawn for assay testing within the required time frames at Visit 1 (before Vaccination 1) and 1 month after Vaccination 2 (28-42 days after Visit 3), had at least 1 valid and determinate assay result 1 month after Vaccination 2, received no prohibited vaccines or medications through Visit 4, and had no major protocol deviations through Visit 4.

    Time frame: Baseline (Before Vaccination 1 on Day 1/Month 0)

  2. Percentage of Participants With hSBA Titer => LLOQ for Each of the 4 Primary MnB Test Strains at 1 Month After Vaccination 2

    Four primary MnB strains were PMB80 (A22), PMB2001 (A56), PMB2948 (B24) and PMB2707 (B44). The percentage of participants who achieved an hSBA titer PMB80 (A22) =\>1:16, and hSBA titer PMB2001 (A56), PMB2001 (B24), and PMB2707 (B44) =\>1:8 were reported.

    Time frame: 1 Month after Vaccination 2 (Vaccination 2 at Month 6)

  3. Percentage of Participants Reporting Local Reactions Within 7 Days After Vaccination 1

    Local reactions (redness, swelling, and pain) at the site of investigational product administration were recorded in electronic diary (e-diary). Redness and swelling were measured and recorded in caliper units. Each caliper unit = 0.5 centimeter (cm). Redness and swelling were graded as mild (more than \[\>\]2.0 to 5.0cm), moderate (\>5.0 to 10.0cm) and severe (\>10.0cm). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), and severe (prevented daily activity).

    Time frame: Within 7 Days after Vaccination 1 (Vaccination 1 on Day 1/Month 0)

  4. Percentage of Participants Reporting Local Reactions Within 7 Days After Vaccination 2

    Local reactions (redness, swelling, and pain) at the site of investigational product administration were recorded in electronic diary (e-diary). Redness and swelling were measured and recorded in caliper units. Each caliper unit = 0.5 cm. Redness and swelling were graded as mild (\>2.0 to 5.0cm), moderate (\>5.0 to 10.0cm) and severe (\>10.0cm). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), and severe (prevented daily activity).

    Time frame: Within 7 Days after Vaccination 2 (Vaccination 2 at Month 6)

  5. Percentage of Participants Reporting Systemic Events Within 7 Days After Vaccination 1

    Systemic events included: fever, fatigue, headache, chills, muscle pain, joint pain, vomiting, and diarrhea. Fever classified as =\>38.0 degree Celsius (C), 38.0-38.4, \>38.4-38.9, \>38.9 40.0 and \>40.0-degree C. Fatigue, headache, chills, muscle pain and joint pain graded as mild (did not interfere with activity), moderate (some interference with activity) and severe (prevented daily activity). Vomiting graded as mild (1-2 times in 24 hours \[hrs\]), moderate (\>2 times in 24 hrs) and severe (required intravenous \[IV\] hydration). Diarrhea graded as mild (2-3 loose stools in 24 hrs), moderate (4-5 loose stools in 24 hrs) and severe (=\>6 in 24 hrs).

    Time frame: Within 7 Days after Vaccination 1 (Vaccination 1 on Day 1/Month 0)

  6. Percentage of Participants Reporting Systemic Events Within 7 Days After Vaccination 2

    Systemic events included: fever, fatigue, headache, chills, muscle pain, joint pain, vomiting, and diarrhea. Fever classified as =\>38.0 degree C, 38.0-38.4, \>38.4-38.9, \>38.9 40.0 and \>40.0-degree C. Fatigue, headache, chills, muscle pain and joint pain graded as mild (did not interfere with activity), moderate (some interference with activity) and severe (prevented daily activity). Vomiting graded as mild (1-2 times in 24 hrs), moderate (\>2 times in 24 hrs) and severe (required IV hydration). Diarrhea graded as mild (2-3 loose stools in 24 hrs), moderate (4-5 loose stools in 24 hrs) and severe (=\>6 in 24 hrs).

    Time frame: Within 7 Days after Vaccination 2 (Vaccination 2 at Month 6)

  7. Percentage of Participants Reporting Use of Antipyretic Medication Within 7 Days After Vaccination 1

    Time frame: Within 7 Days after Vaccination 1 (Vaccination 1 on Day 1/Month 0)

  8. Percentage of Participants Reporting Use of Antipyretic Medication Within 7 Days After Vaccination 2

    Time frame: Within 7 Days after Vaccination 2 (Vaccination 2 at Month 6)

  9. Percentage of Participants Reporting Adverse Events (AEs) During 30 Days After Vaccination 1

    An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs excluded local reactions and systematic events.

    Time frame: 30 Days after Vaccination 1 (Vaccination 1 on Day 1/Month 0)

  10. Percentage of Participants Reporting AEs During 30 Days After Vaccination 2

    An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs excluded local reactions and systematic events.

    Time frame: 30 Days after Vaccination 2 (Vaccination 2 at Month 6)

  11. Percentage of Participants Reporting AEs During 30 Days After Any Vaccination

    An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs excluded local reactions and systematic events.

    Time frame: 30 Days after any Vaccination

  12. Percentage of Participants Reporting AEs During the Vaccination Phase

    An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs excluded local reactions and systematic events.

    Time frame: Vaccination Phase: From Vaccination 1 through one Month after Vaccination 2 (approximately 7 Months)

  13. Percentage of Participants Reporting Serious Adverse Events (SAEs) During 30 Days After Vaccination 1

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect or that was considered to be an important medical event.

    Time frame: 30 Days after Vaccination 1 (Vaccination 1 on Day 1/Month 0)

  14. Percentage of Participants Reporting SAEs During 30 Days After Vaccination 2

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect or that was considered to be an important medical event.

    Time frame: 30 Days after Vaccination 2 (Vaccination 2 at Month 6)

  15. Percentage of Participants Reporting SAEs During 30 Days After Any Vaccination

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect or that was considered to be an important medical event.

    Time frame: 30 Days after any Vaccination

  16. Percentage of Participants Reporting SAEs During the Vaccination Phase

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect or that was considered to be an important medical event.

    Time frame: Vaccination Phase: From Vaccination 1 through 1 Month after Vaccination 2 (approximately 7 Months)

  17. Percentage of Participants Reporting SAEs During the Follow-up Phase

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect or that was considered to be an important medical event.

    Time frame: Follow-up Phase: From 1 Month after Vaccination 2 through 6 Months after Vaccination 2 (approximately 5 Months)

  18. Percentage of Participants Reporting SAEs During the Entire Study

    An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect. Or that was considered to be an important medical event.

    Time frame: Entire Study: From Vaccination 1 through 6 Months after Vaccination 2 (approximately 12 Months)

  19. Percentage of Participants Reporting Medically Attended Adverse Event (MAEs) During 30 Days After Vaccination 1

    MAEs was defined as a nonserious AE that resulted in an evaluation at a medical facility.

    Time frame: 30 Days after Vaccination 1 (Vaccination 1 on Day 1/Month 0)

  20. Percentage of Participants Reporting MAEs During 30 Days After Vaccination 2

    MAEs was defined as a nonserious AE that resulted in an evaluation at a medical facility.

    Time frame: 30 Days after Vaccination 2 (Vaccination 2 at Month 6)

  21. Percentage of Participants Reporting MAEs During 30 Days After Any Vaccination

    MAEs was defined as a nonserious AE that resulted in an evaluation at a medical facility.

    Time frame: 30 Days after any Vaccination

  22. Percentage of Participants Reporting MAEs During the Vaccination Phase

    MAEs was defined as a nonserious AE that resulted in an evaluation at a medical facility.

    Time frame: Vaccination Phase: From Vaccination 1 through 1 Month after Vaccination 2 (approximately 7 Months)

  23. Percentage of Participants Reporting MAEs During the Follow-up Phase

    MAEs was defined as a nonserious AE that resulted in an evaluation at a medical facility.

    Time frame: Follow-up Phase: From 1 Month after Vaccination 2 through 6 Months after Vaccination 2 (approximately 5 Months)

  24. Percentage of Participants Reporting MAEs During the Entire Study

    MAEs was defined as a nonserious AE that resulted in an evaluation at a medical facility.

    Time frame: Entire Study: From Vaccination 1 through 6 Months after Vaccination 2 (approximately 12 Months)

  25. Percentage of Participants Reporting Immediate AEs After Vaccination 1

    Immediate AE was defined as AE occurring within the first 30 minutes after study intervention administration.

    Time frame: 30 Minutes post Vaccination 1 (Vaccination 1 on Day 1/Month 0)

  26. Percentage of Participants Reporting Immediate AEs After Vaccination 2

    Immediate AE was defined as AE occurring within the first 30 minutes after study intervention administration.

    Time frame: 30 Minutes post Vaccination 2 (Vaccination 2 at Month 6)

  27. Percentage of Participants With Newly Diagnosed Chronic Medical Condition (NDCMC) During the Vaccination Phase

    A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.

    Time frame: Vaccination Phase: From Vaccination 1 through 1 Month after Vaccination 2 (approximately 7 Months)

  28. Percentage of Participants With NDCMC During the Follow-up Phase

    A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.

    Time frame: Follow-up Phase: From 1 Month after Vaccination 2 through 6 Months after Vaccination 2 (approximately 5 Months)

  29. Percentage of Participants With NDCMC During the Entire Study

    A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.

    Time frame: Entire Study: From Vaccination 1 through 6 Months after Vaccination 2 (approximately 12 Months)

  30. Mean Number of Days Participants Missed School or Work Because of AEs During the Vaccination Phase

    An AE is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

    Time frame: Vaccination Phase: From Vaccination 1 through 1 Month after Vaccination 2 (approximately 7 Months)

07

Results

Posted Oct 16, 2024

Participant flow

A total of 53 immunocompromised participants greater than or equal to (\>=) 10 years of age with asplenia (anatomic or functional) or complement deficiency were enrolled and received Trumenba on a 2-dose, 0- and 6-month schedule in the Study B1971060 \[NCT04893811\].

Vaccination Phase
Participant flow — Vaccination Phase
MilestoneTrumenba (B1971060)Trumenba (B1971057, Historical Age- and Sex-Matched Control)
Started5351
Vaccination 15351
Vaccination 24747
Completed4747
Not completed64
Withdrew: Death10
Withdrew: Lost to follow-up11
Withdrew: Protocol violation20
Withdrew: Withdrawal by subject21
Withdrew: Other01
Withdrew: No longer met eligibility criteria01
Follow-up Phase
Participant flow — Follow-up Phase
MilestoneTrumenba (B1971060)Trumenba (B1971057, Historical Age- and Sex-Matched Control)
Started4747
Follow-up safety set4448
Completed4746
Not completed01
Withdrew: Lost to follow-up01

Outcome measures

PrimaryPercentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer => Lower Limit of Quantitation (LLOQ) for Each of the 4 Primary Neisseria Meningitidis Serogroup B (MnB) Test Strains at Baseline

Four primary MnB strains were PMB80 (A22), PMB2001 (A56), PMB2948 (B24) and PMB2707 (B44). The percentage of participants who achieved an hSBA titer PMB80 (A22) more than or equal to (=\>)1:16, and hSBA titer PMB2001 (A56), PMB2001 (B24), and PMB2707 (B44) =\>1:8 are reported. Evaluable immunogenicity population (EIP) included all participants who were eligible through 1 month after Vaccination 2, received the study vaccination at Visit 1 and Visit 3 as planned, had blood drawn for assay testing within the required time frames at Visit 1 (before Vaccination 1) and 1 month after Vaccination 2 (28-42 days after Visit 3), had at least 1 valid and determinate assay result 1 month after Vaccination 2, received no prohibited vaccines or medications through Visit 4, and had no major protocol deviations through Visit 4.

Time frame:
Baseline (Before Vaccination 1 on Day 1/Month 0)
Reported as:
Number · Percentage of participants
Percentage of Participants With Serum Bactericidal Assay Using Human Complement (hSBA) Titer => Lower Limit of Quantitation (LLOQ) for Each of the 4 Primary Neisseria Meningitidis Serogroup B (MnB) Test Strains at Baseline
Percentage of participantsTrumenba (B1971060)Trumenba (B1971057, Historical Age- and Sex-Matched Control)
PMB80 (A22)32.6 (19.1 to 48.5)31.0 (17.6 to 47.1)
PMB2001 (A56)25.6 (13.5 to 41.2)23.3 (11.8 to 38.6)
PMB2948 (B24)2.4 (0.1 to 12.6)23.3 (11.8 to 38.6)
PMB2707 (B44)9.3 (2.6 to 22.1)11.4 (3.8 to 24.6)
PrimaryPercentage of Participants With hSBA Titer => LLOQ for Each of the 4 Primary MnB Test Strains at 1 Month After Vaccination 2

Four primary MnB strains were PMB80 (A22), PMB2001 (A56), PMB2948 (B24) and PMB2707 (B44). The percentage of participants who achieved an hSBA titer PMB80 (A22) =\>1:16, and hSBA titer PMB2001 (A56), PMB2001 (B24), and PMB2707 (B44) =\>1:8 were reported.

Time frame:
1 Month after Vaccination 2 (Vaccination 2 at Month 6)
Reported as:
Number · Percentage of participants
Percentage of Participants With hSBA Titer => LLOQ for Each of the 4 Primary MnB Test Strains at 1 Month After Vaccination 2
Percentage of participantsTrumenba (B1971060)Trumenba (B1971057, Historical Age- and Sex-Matched Control)
PMB80 (A22)75.0 (59.7 to 86.8)95.3 (84.2 to 99.4)
PMB2001 (A56)90.9 (78.3 to 97.5)100.0 (92.0 to 100.0)
PMB2948 (B24)70.5 (54.8 to 83.2)81.8 (67.3 to 91.8)
PMB2707 (B44)79.1 (64.0 to 90.0)92.9 (80.5 to 98.5)
PrimaryPercentage of Participants Reporting Local Reactions Within 7 Days After Vaccination 1

Local reactions (redness, swelling, and pain) at the site of investigational product administration were recorded in electronic diary (e-diary). Redness and swelling were measured and recorded in caliper units. Each caliper unit = 0.5 centimeter (cm). Redness and swelling were graded as mild (more than \[\>\]2.0 to 5.0cm), moderate (\>5.0 to 10.0cm) and severe (\>10.0cm). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), and severe (prevented daily activity).

Time frame:
Within 7 Days after Vaccination 1 (Vaccination 1 on Day 1/Month 0)
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Local Reactions Within 7 Days After Vaccination 1
Percentage of participantsTrumenba (B1971060)Trumenba (B1971057, Historical Age- and Sex-Matched Control)
Redness: Any18.9 (9.4 to 32.0)11.8 (4.4 to 23.9)
Redness: Mild5.7 (1.2 to 15.7)5.9 (1.2 to 16.2)
Redness: Moderate9.4 (3.1 to 20.7)3.9 (0.5 to 13.5)
Redness: Severe3.8 (0.5 to 13.0)2.0 (0.0 to 10.4)
Swelling: Any22.6 (12.3 to 36.2)11.8 (4.4 to 23.9)
Swelling: Mild7.5 (2.1 to 18.2)7.8 (2.2 to 18.9)
Swelling: Moderate15.1 (6.7 to 27.6)3.9 (0.5 to 13.5)
Swelling: Severe0 (0.0 to 6.7)0 (0.0 to 7.0)
Pain at injection site: Any86.8 (74.7 to 94.5)80.4 (66.9 to 90.2)
Pain at injection site: Mild41.5 (28.1 to 55.9)47.1 (32.9 to 61.5)
Pain at injection site: Moderate32.1 (19.9 to 46.3)33.3 (20.8 to 47.9)
Pain at injection site: Severe13.2 (5.5 to 25.3)0 (0.0 to 7.0)
PrimaryPercentage of Participants Reporting Local Reactions Within 7 Days After Vaccination 2

Local reactions (redness, swelling, and pain) at the site of investigational product administration were recorded in electronic diary (e-diary). Redness and swelling were measured and recorded in caliper units. Each caliper unit = 0.5 cm. Redness and swelling were graded as mild (\>2.0 to 5.0cm), moderate (\>5.0 to 10.0cm) and severe (\>10.0cm). Pain at injection site was graded as mild (did not interfere with activity), moderate (interfered with activity), and severe (prevented daily activity).

Time frame:
Within 7 Days after Vaccination 2 (Vaccination 2 at Month 6)
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Local Reactions Within 7 Days After Vaccination 2
Percentage of participantsTrumenba (B1971060)Trumenba (B1971057, Historical Age- and Sex-Matched Control)
Redness: Any20.0 (9.6 to 34.6)7.0 (1.5 to 19.1)
Redness: Mild6.7 (1.4 to 18.3)2.3 (0.1 to 12.3)
Redness: Moderate11.1 (3.7 to 24.1)4.7 (0.6 to 15.8)
Redness: Severe2.2 (0.1 to 11.8)0 (0.0 to 8.2)
Swelling: Any26.7 (14.6 to 41.9)4.7 (0.6 to 15.8)
Swelling: Mild13.3 (5.1 to 26.8)0 (0.0 to 8.2)
Swelling: Moderate13.3 (5.1 to 26.8)4.7 (0.6 to 15.8)
Swelling: Severe0 (0.0 to 7.9)0 (0.0 to 8.2)
Pain at injection site: Any93.3 (81.7 to 98.6)60.5 (44.4 to 75.0)
Pain at injection site: Mild44.4 (29.6 to 60.0)30.2 (17.2 to 46.1)
Pain at injection site: Moderate35.6 (21.9 to 51.2)27.9 (15.3 to 43.7)
Pain at injection site: Severe13.3 (5.1 to 26.8)2.3 (0.1 to 12.3)
PrimaryPercentage of Participants Reporting Systemic Events Within 7 Days After Vaccination 1

Systemic events included: fever, fatigue, headache, chills, muscle pain, joint pain, vomiting, and diarrhea. Fever classified as =\>38.0 degree Celsius (C), 38.0-38.4, \>38.4-38.9, \>38.9 40.0 and \>40.0-degree C. Fatigue, headache, chills, muscle pain and joint pain graded as mild (did not interfere with activity), moderate (some interference with activity) and severe (prevented daily activity). Vomiting graded as mild (1-2 times in 24 hours \[hrs\]), moderate (\>2 times in 24 hrs) and severe (required intravenous \[IV\] hydration). Diarrhea graded as mild (2-3 loose stools in 24 hrs), moderate (4-5 loose stools in 24 hrs) and severe (=\>6 in 24 hrs).

Time frame:
Within 7 Days after Vaccination 1 (Vaccination 1 on Day 1/Month 0)
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Systemic Events Within 7 Days After Vaccination 1
Percentage of participantsTrumenba (B1971060)Trumenba (B1971057, Historical Age- and Sex-Matched Control)
Fever: =>38.0 degree C3.8 (0.5 to 13.0)2.0 (0.0 to 10.4)
Fever: 38.0 to 38.4 degree C1.9 (0.0 to 10.1)0 (0.0 to 7.0)
Fever: >38.4 to 38.9 degree C0 (0.0 to 6.7)2.0 (0.0 to 10.4)
Fever: >38.9 to 40.0 degree C1.9 (0.0 to 10.1)0 (0.0 to 7.0)
Fever: >40.0 degree C0 (0.0 to 6.7)0 (0.0 to 7.0)
Fatigue: Any54.7 (40.4 to 68.4)51.0 (36.6 to 65.2)
Fatigue: Mild26.4 (15.3 to 40.3)39.2 (25.8 to 53.9)
Fatigue: Moderate22.6 (12.3 to 36.2)11.8 (4.4 to 23.9)
Fatigue: Severe5.7 (1.2 to 15.7)0 (0.0 to 7.0)
Headache: Any41.5 (28.1 to 55.9)29.4 (17.5 to 43.8)
Headache: Mild18.9 (9.4 to 32.0)25.5 (14.3 to 39.6)
Headache: Moderate18.9 (9.4 to 32.0)2.0 (0.0 to 10.4)
Headache: Severe3.8 (0.5 to 13.0)2.0 (0.0 to 10.4)
Chills: Any15.1 (6.7 to 27.6)19.6 (9.8 to 33.1)
Chills: Mild11.3 (4.3 to 23.0)17.6 (8.4 to 30.9)
Chills: Moderate1.9 (0.0 to 10.1)2.0 (0.0 to 10.4)
Chills: Severe1.9 (0.0 to 10.1)0 (0.0 to 7.0)
Muscle Pain: Any26.4 (15.3 to 40.3)23.5 (12.8 to 37.5)
Muscle Pain: Mild15.1 (6.7 to 27.6)11.8 (4.4 to 23.9)
Muscle Pain: Moderate9.4 (3.1 to 20.7)9.8 (3.3 to 21.4)
Muscle Pain: Severe1.9 (0.0 to 10.1)2.0 (0.0 to 10.4)
Joint Pain: Any22.6 (12.3 to 36.2)19.6 (9.8 to 33.1)
Joint Pain: Mild9.4 (3.1 to 20.7)11.8 (4.4 to 23.9)
Joint Pain: Moderate9.4 (3.1 to 20.7)5.9 (1.2 to 16.2)
Joint Pain: Severe3.8 (0.5 to 13.0)2.0 (0.0 to 10.4)
Vomiting: Any1.9 (0.0 to 10.1)2.0 (0.0 to 10.4)
Vomiting: Mild1.9 (0.0 to 10.1)2.0 (0.0 to 10.4)
Vomiting: Moderate0 (0.0 to 6.7)0 (0.0 to 7.0)
Vomiting: Severe0 (0.0 to 6.7)0 (0.0 to 7.0)
Diarrhea: Any9.4 (3.1 to 20.7)11.8 (4.4 to 23.9)
Diarrhea: Mild9.4 (3.1 to 20.7)5.9 (1.2 to 16.2)
Diarrhea: Moderate0 (0.0 to 6.7)5.9 (1.2 to 16.2)
Diarrhea: Severe0 (0.0 to 6.7)0 (0.0 to 7.0)
PrimaryPercentage of Participants Reporting Systemic Events Within 7 Days After Vaccination 2

Systemic events included: fever, fatigue, headache, chills, muscle pain, joint pain, vomiting, and diarrhea. Fever classified as =\>38.0 degree C, 38.0-38.4, \>38.4-38.9, \>38.9 40.0 and \>40.0-degree C. Fatigue, headache, chills, muscle pain and joint pain graded as mild (did not interfere with activity), moderate (some interference with activity) and severe (prevented daily activity). Vomiting graded as mild (1-2 times in 24 hrs), moderate (\>2 times in 24 hrs) and severe (required IV hydration). Diarrhea graded as mild (2-3 loose stools in 24 hrs), moderate (4-5 loose stools in 24 hrs) and severe (=\>6 in 24 hrs).

Time frame:
Within 7 Days after Vaccination 2 (Vaccination 2 at Month 6)
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Systemic Events Within 7 Days After Vaccination 2
Percentage of participantsTrumenba (B1971060)Trumenba (B1971057, Historical Age- and Sex-Matched Control)
Fever: =>38.0 degree C2.2 (0.1 to 11.8)2.3 (0.1 to 12.3)
Fever: 38.0 to 38.4 degree C2.2 (0.1 to 11.8)0 (0.0 to 8.2)
Fever: >38.4 to 38.9 degree C0 (0.0 to 7.9)2.3 (0.1 to 12.3)
Fever: >38.9 to 40.0 degree C0 (0.0 to 7.9)0 (0.0 to 8.2)
Fever: >40.0 degree C0 (0.0 to 7.9)0 (0.0 to 8.2)
Fatigue: Any53.3 (37.9 to 68.3)41.9 (27.0 to 57.9)
Fatigue: Mild24.4 (12.9 to 39.5)23.3 (11.8 to 38.6)
Fatigue: Moderate24.4 (12.9 to 39.5)14.0 (5.3 to 27.9)
Fatigue: Severe4.4 (0.5 to 15.1)4.7 (0.6 to 15.8)
Headache: Any35.6 (21.9 to 51.2)30.2 (17.2 to 46.1)
Headache: Mild6.7 (1.4 to 18.3)23.3 (11.8 to 38.6)
Headache: Moderate22.2 (11.2 to 37.1)7.0 (1.5 to 19.1)
Headache: Severe6.7 (1.4 to 18.3)0 (0.0 to 8.2)
Chills: Any8.9 (2.5 to 21.2)14.0 (5.3 to 27.9)
Chills: Mild4.4 (0.5 to 15.1)11.6 (3.9 to 25.1)
Chills: Moderate2.2 (0.1 to 11.8)2.3 (0.1 to 12.3)
Chills: Severe2.2 (0.1 to 11.8)0 (0.0 to 8.2)
Muscle Pain: Any13.3 (5.1 to 26.8)11.6 (3.9 to 25.1)
Muscle Pain: Mild4.4 (0.5 to 15.1)7.0 (1.5 to 19.1)
Muscle Pain: Moderate8.9 (2.5 to 21.2)2.3 (0.1 to 12.3)
Muscle Pain: Severe0 (0.0 to 7.9)2.3 (0.1 to 12.3)
Joint Pain: Any20.0 (9.6 to 34.6)16.3 (6.8 to 30.7)
Joint Pain: Mild6.7 (1.4 to 18.3)14.0 (5.3 to 27.9)
Joint Pain: Moderate11.1 (3.7 to 24.1)0 (0.0 to 8.2)
Joint Pain: Severe2.2 (0.1 to 11.8)2.3 (0.1 to 12.3)
Vomiting: Any2.2 (0.1 to 11.8)0 (0.0 to 8.2)
Vomiting: Mild2.2 (0.1 to 11.8)0 (0.0 to 8.2)
Vomiting: Moderate0 (0.0 to 7.9)0 (0.0 to 8.2)
Vomiting: Severe0 (0.0 to 7.9)0 (0.0 to 8.2)
Diarrhea: Any8.9 (2.5 to 21.2)4.7 (0.6 to 15.8)
Diarrhea: Mild6.7 (1.4 to 18.3)4.7 (0.6 to 15.8)
Diarrhea: Moderate2.2 (0.1 to 11.8)0 (0.0 to 8.2)
Diarrhea: Severe0 (0.0 to 7.9)0 (0.0 to 8.2)
PrimaryPercentage of Participants Reporting Use of Antipyretic Medication Within 7 Days After Vaccination 1
Time frame:
Within 7 Days after Vaccination 1 (Vaccination 1 on Day 1/Month 0)
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Use of Antipyretic Medication Within 7 Days After Vaccination 1
Percentage of participantsTrumenba (B1971060)Trumenba (B1971057, Historical Age- and Sex-Matched Control)
Percentage of Participants Reporting Use of Antipyretic Medication Within 7 Days After Vaccination 134.0 (21.5 to 48.3)9.8 (3.3 to 21.4)
PrimaryPercentage of Participants Reporting Use of Antipyretic Medication Within 7 Days After Vaccination 2
Time frame:
Within 7 Days after Vaccination 2 (Vaccination 2 at Month 6)
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Use of Antipyretic Medication Within 7 Days After Vaccination 2
Percentage of participantsTrumenba (B1971060)Trumenba (B1971057, Historical Age- and Sex-Matched Control)
Percentage of Participants Reporting Use of Antipyretic Medication Within 7 Days After Vaccination 228.9 (16.4 to 44.3)7.0 (1.5 to 19.1)
PrimaryPercentage of Participants Reporting Adverse Events (AEs) During 30 Days After Vaccination 1

An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs excluded local reactions and systematic events.

Time frame:
30 Days after Vaccination 1 (Vaccination 1 on Day 1/Month 0)
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Adverse Events (AEs) During 30 Days After Vaccination 1
Percentage of participantsTrumenba (B1971060)Trumenba (B1971057, Historical Age- and Sex-Matched Control)
Percentage of Participants Reporting Adverse Events (AEs) During 30 Days After Vaccination 126.4 (15.3 to 40.3)9.8 (3.3 to 21.4)
PrimaryPercentage of Participants Reporting AEs During 30 Days After Vaccination 2

An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs excluded local reactions and systematic events.

Time frame:
30 Days after Vaccination 2 (Vaccination 2 at Month 6)
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting AEs During 30 Days After Vaccination 2
Percentage of participantsTrumenba (B1971060)Trumenba (B1971057, Historical Age- and Sex-Matched Control)
Percentage of Participants Reporting AEs During 30 Days After Vaccination 212.8 (4.8 to 25.7)12.8 (4.8 to 25.7)
PrimaryPercentage of Participants Reporting AEs During 30 Days After Any Vaccination

An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs excluded local reactions and systematic events.

Time frame:
30 Days after any Vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting AEs During 30 Days After Any Vaccination
Percentage of participantsTrumenba (B1971060)Trumenba (B1971057, Historical Age- and Sex-Matched Control)
Percentage of Participants Reporting AEs During 30 Days After Any Vaccination34.0 (21.5 to 48.3)17.6 (8.4 to 30.9)
PrimaryPercentage of Participants Reporting AEs During the Vaccination Phase

An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs excluded local reactions and systematic events.

Time frame:
Vaccination Phase: From Vaccination 1 through one Month after Vaccination 2 (approximately 7 Months)
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting AEs During the Vaccination Phase
Percentage of participantsTrumenba (B1971060)Trumenba (B1971057, Historical Age- and Sex-Matched Control)
Percentage of Participants Reporting AEs During the Vaccination Phase60.4 (46.0 to 73.5)41.2 (27.6 to 55.8)
PrimaryPercentage of Participants Reporting Serious Adverse Events (SAEs) During 30 Days After Vaccination 1

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect or that was considered to be an important medical event.

Time frame:
30 Days after Vaccination 1 (Vaccination 1 on Day 1/Month 0)
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Serious Adverse Events (SAEs) During 30 Days After Vaccination 1
Percentage of participantsTrumenba (B1971060)Trumenba (B1971057, Historical Age- and Sex-Matched Control)
Percentage of Participants Reporting Serious Adverse Events (SAEs) During 30 Days After Vaccination 19.4 (3.1 to 20.7)0 (0.0 to 7.0)
PrimaryPercentage of Participants Reporting SAEs During 30 Days After Vaccination 2

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect or that was considered to be an important medical event.

Time frame:
30 Days after Vaccination 2 (Vaccination 2 at Month 6)
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting SAEs During 30 Days After Vaccination 2
Percentage of participantsTrumenba (B1971060)Trumenba (B1971057, Historical Age- and Sex-Matched Control)
Percentage of Participants Reporting SAEs During 30 Days After Vaccination 20 (0.0 to 7.5)0 (0.0 to 7.5)
PrimaryPercentage of Participants Reporting SAEs During 30 Days After Any Vaccination

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect or that was considered to be an important medical event.

Time frame:
30 Days after any Vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting SAEs During 30 Days After Any Vaccination
Percentage of participantsTrumenba (B1971060)Trumenba (B1971057, Historical Age- and Sex-Matched Control)
Percentage of Participants Reporting SAEs During 30 Days After Any Vaccination9.4 (3.1 to 20.7)0 (0.0 to 7.0)
PrimaryPercentage of Participants Reporting SAEs During the Vaccination Phase

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect or that was considered to be an important medical event.

Time frame:
Vaccination Phase: From Vaccination 1 through 1 Month after Vaccination 2 (approximately 7 Months)
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting SAEs During the Vaccination Phase
Percentage of participantsTrumenba (B1971060)Trumenba (B1971057, Historical Age- and Sex-Matched Control)
Percentage of Participants Reporting SAEs During the Vaccination Phase17.0 (8.1 to 29.8)0 (0.0 to 7.0)
PrimaryPercentage of Participants Reporting SAEs During the Follow-up Phase

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect or that was considered to be an important medical event.

Time frame:
Follow-up Phase: From 1 Month after Vaccination 2 through 6 Months after Vaccination 2 (approximately 5 Months)
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting SAEs During the Follow-up Phase
Percentage of participantsTrumenba (B1971060)Trumenba (B1971057, Historical Age- and Sex-Matched Control)
Percentage of Participants Reporting SAEs During the Follow-up Phase4.5 (0.6 to 15.5)2.1 (0.1 to 11.1)
PrimaryPercentage of Participants Reporting SAEs During the Entire Study

An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAE was any untoward medical occurrence at any dose that: resulted in death, was life threatening (immediate risk of death), required hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity (substantial disruption of the ability to conduct normal life functions), resulted in congenital anomaly/birth defect. Or that was considered to be an important medical event.

Time frame:
Entire Study: From Vaccination 1 through 6 Months after Vaccination 2 (approximately 12 Months)
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting SAEs During the Entire Study
Percentage of participantsTrumenba (B1971060)Trumenba (B1971057, Historical Age- and Sex-Matched Control)
Percentage of Participants Reporting SAEs During the Entire Study18.9 (9.4 to 32.0)2.0 (0.0 to 10.4)
PrimaryPercentage of Participants Reporting Medically Attended Adverse Event (MAEs) During 30 Days After Vaccination 1

MAEs was defined as a nonserious AE that resulted in an evaluation at a medical facility.

Time frame:
30 Days after Vaccination 1 (Vaccination 1 on Day 1/Month 0)
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Medically Attended Adverse Event (MAEs) During 30 Days After Vaccination 1
Percentage of participantsTrumenba (B1971060)Trumenba (B1971057, Historical Age- and Sex-Matched Control)
Percentage of Participants Reporting Medically Attended Adverse Event (MAEs) During 30 Days After Vaccination 120.8 (10.8 to 34.1)5.9 (1.2 to 16.2)
PrimaryPercentage of Participants Reporting MAEs During 30 Days After Vaccination 2

MAEs was defined as a nonserious AE that resulted in an evaluation at a medical facility.

Time frame:
30 Days after Vaccination 2 (Vaccination 2 at Month 6)
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting MAEs During 30 Days After Vaccination 2
Percentage of participantsTrumenba (B1971060)Trumenba (B1971057, Historical Age- and Sex-Matched Control)
Percentage of Participants Reporting MAEs During 30 Days After Vaccination 212.8 (4.8 to 25.7)4.3 (0.5 to 14.5)
PrimaryPercentage of Participants Reporting MAEs During 30 Days After Any Vaccination

MAEs was defined as a nonserious AE that resulted in an evaluation at a medical facility.

Time frame:
30 Days after any Vaccination
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting MAEs During 30 Days After Any Vaccination
Percentage of participantsTrumenba (B1971060)Trumenba (B1971057, Historical Age- and Sex-Matched Control)
Percentage of Participants Reporting MAEs During 30 Days After Any Vaccination30.2 (18.3 to 44.3)9.8 (3.3 to 21.4)
PrimaryPercentage of Participants Reporting MAEs During the Vaccination Phase

MAEs was defined as a nonserious AE that resulted in an evaluation at a medical facility.

Time frame:
Vaccination Phase: From Vaccination 1 through 1 Month after Vaccination 2 (approximately 7 Months)
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting MAEs During the Vaccination Phase
Percentage of participantsTrumenba (B1971060)Trumenba (B1971057, Historical Age- and Sex-Matched Control)
Percentage of Participants Reporting MAEs During the Vaccination Phase54.7 (40.4 to 68.4)29.4 (17.5 to 43.8)
PrimaryPercentage of Participants Reporting MAEs During the Follow-up Phase

MAEs was defined as a nonserious AE that resulted in an evaluation at a medical facility.

Time frame:
Follow-up Phase: From 1 Month after Vaccination 2 through 6 Months after Vaccination 2 (approximately 5 Months)
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting MAEs During the Follow-up Phase
Percentage of participantsTrumenba (B1971060)Trumenba (B1971057, Historical Age- and Sex-Matched Control)
Percentage of Participants Reporting MAEs During the Follow-up Phase15.9 (6.6 to 30.1)10.4 (3.5 to 22.7)
PrimaryPercentage of Participants Reporting MAEs During the Entire Study

MAEs was defined as a nonserious AE that resulted in an evaluation at a medical facility.

Time frame:
Entire Study: From Vaccination 1 through 6 Months after Vaccination 2 (approximately 12 Months)
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting MAEs During the Entire Study
Percentage of participantsTrumenba (B1971060)Trumenba (B1971057, Historical Age- and Sex-Matched Control)
Percentage of Participants Reporting MAEs During the Entire Study60.4 (46.0 to 73.5)31.4 (19.1 to 45.9)
PrimaryPercentage of Participants Reporting Immediate AEs After Vaccination 1

Immediate AE was defined as AE occurring within the first 30 minutes after study intervention administration.

Time frame:
30 Minutes post Vaccination 1 (Vaccination 1 on Day 1/Month 0)
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Immediate AEs After Vaccination 1
Percentage of participantsTrumenba (B1971060)Trumenba (B1971057, Historical Age- and Sex-Matched Control)
Percentage of Participants Reporting Immediate AEs After Vaccination 10 (0.0 to 6.7)2.0 (0.0 to 10.4)
PrimaryPercentage of Participants Reporting Immediate AEs After Vaccination 2

Immediate AE was defined as AE occurring within the first 30 minutes after study intervention administration.

Time frame:
30 Minutes post Vaccination 2 (Vaccination 2 at Month 6)
Reported as:
Number · Percentage of participants
Percentage of Participants Reporting Immediate AEs After Vaccination 2
Percentage of participantsTrumenba (B1971060)Trumenba (B1971057, Historical Age- and Sex-Matched Control)
Percentage of Participants Reporting Immediate AEs After Vaccination 20 (0.0 to 7.5)0 (0.0 to 7.5)
PrimaryPercentage of Participants With Newly Diagnosed Chronic Medical Condition (NDCMC) During the Vaccination Phase

A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.

Time frame:
Vaccination Phase: From Vaccination 1 through 1 Month after Vaccination 2 (approximately 7 Months)
Reported as:
Number · Percentage of participants
Percentage of Participants With Newly Diagnosed Chronic Medical Condition (NDCMC) During the Vaccination Phase
Percentage of participantsTrumenba (B1971060)Trumenba (B1971057, Historical Age- and Sex-Matched Control)
Percentage of Participants With Newly Diagnosed Chronic Medical Condition (NDCMC) During the Vaccination Phase1.9 (0.0 to 10.1)0 (0.0 to 7.0)
PrimaryPercentage of Participants With NDCMC During the Follow-up Phase

A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.

Time frame:
Follow-up Phase: From 1 Month after Vaccination 2 through 6 Months after Vaccination 2 (approximately 5 Months)
Reported as:
Number · Percentage of participants
Percentage of Participants With NDCMC During the Follow-up Phase
Percentage of participantsTrumenba (B1971060)Trumenba (B1971057, Historical Age- and Sex-Matched Control)
Percentage of Participants With NDCMC During the Follow-up Phase0 (0.0 to 8.0)0 (0.0 to 7.4)
PrimaryPercentage of Participants With NDCMC During the Entire Study

A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or otherwise long-lasting in its effects.

Time frame:
Entire Study: From Vaccination 1 through 6 Months after Vaccination 2 (approximately 12 Months)
Reported as:
Number · Percentage of participants
Percentage of Participants With NDCMC During the Entire Study
Percentage of participantsTrumenba (B1971060)Trumenba (B1971057, Historical Age- and Sex-Matched Control)
Percentage of Participants With NDCMC During the Entire Study1.9 (0.0 to 10.1)0 (0.0 to 7.0)
PrimaryMean Number of Days Participants Missed School or Work Because of AEs During the Vaccination Phase

An AE is any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention.

Time frame:
Vaccination Phase: From Vaccination 1 through 1 Month after Vaccination 2 (approximately 7 Months)
Reported as:
Mean · Days
Mean Number of Days Participants Missed School or Work Because of AEs During the Vaccination Phase
DaysTrumenba (B1971060)Trumenba (B1971057, Historical Age- and Sex-Matched Control)
Mean Number of Days Participants Missed School or Work Because of AEs During the Vaccination Phase12.7 ± 7.62.5 ± 2.3

Adverse events

Collected over Local reactions, systemic events within 7 days of each vaccination; SAEs and Non-SAEs: From Day 1 of vaccination up to 6 months after last study vaccination (approximately 12 months). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Trumenba (B1971060)1/53 (1.9%)10/53 (18.9%)51/53 (96.2%)
Trumenba (B1971057, Historical Age- and Sex-Matched Control)0/51 (0%)1/51 (2%)49/51 (96.1%)
Most frequent serious events
Most frequent serious events
EventTrumenba (B1971060)Trumenba (B1971057, Historical Age- and Sex-Matched Control)
Sickle cell anaemia with crisisBlood and lymphatic system disorders4/530/51
COVID-19Infections and infestations2/530/51
PneumoniaInfections and infestations0/531/51
Acute myocardial infarctionCardiac disorders1/530/51
Cardiac arrestCardiac disorders1/530/51
BronchiectasisRespiratory, thoracic and mediastinal disorders1/530/51
Pancreatitis chronicGastrointestinal disorders1/530/51
Urinary tract infectionInfections and infestations1/530/51
Femoral neck fractureInjury, poisoning and procedural complications1/530/51
Wrist fractureInjury, poisoning and procedural complications1/530/51
Most frequent other events
Showing 10 of 80
Most frequent other events
EventTrumenba (B1971060)Trumenba (B1971057, Historical Age- and Sex-Matched Control)
Injection site pain (PAIN AT INJECTION SITE)General disorders48/5345/51
Fatigue (FATIGUE)General disorders31/5327/51
Headache (HEADACHE)Nervous system disorders25/5321/51
Swelling (SWELLING)General disorders17/537/51
Myalgia (MUSCLE PAIN)Musculoskeletal and connective tissue disorders16/5314/51
Erythema (REDNESS)Skin and subcutaneous tissue disorders14/536/51
Arthralgia (JOINT PAIN)Musculoskeletal and connective tissue disorders14/5313/51
Chills (CHILLS)General disorders11/5311/51
Diarrhoea (DIARRHEA)Gastrointestinal disorders8/537/51
COVID-19Infections and infestations5/530/51

Baseline characteristics

For B1971060: all enrolled participants who received at least 1 dose of the study Intervention. For B1971057: Historical data of the age- and sex-matched healthy participants (selected randomly) as reference for current study.

Age, Customized
Age, Customized(Participants)Trumenba (B1971060)Trumenba (B1971057, Historical Age- and Sex-Matched Control)Total
2-11 years224
12-17 years8614
18-64 years404383
65-84 years303
Sex: Female, Male
Sex: Female, Male(Participants)Trumenba (B1971060)Trumenba (B1971057, Historical Age- and Sex-Matched Control)Total
Female232144
Male303060
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Trumenba (B1971060)Trumenba (B1971057, Historical Age- and Sex-Matched Control)Total
Hispanic or Latino077
Not Hispanic or Latino534497
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Trumenba (B1971060)Trumenba (B1971057, Historical Age- and Sex-Matched Control)Total
American Indian or Alaska Native000
Asian022
Native Hawaiian or Other Pacific Islander000
Black or African American033
White534699
More than one race000
Unknown or Not Reported000
08

Study locations

14 sites
  • Fakultni Nemocnice Brno - Detska Nemocnice - Klinika Detskych Infekcnich Nemoci Center 3
    Brno 2, 61300, Czechia
  • Fakultni Nemocnice Brno - Detska Nemocnice - Klinika Detskych Infekcnich Nemoci Center 3
    Brno, 613 00, Czechia
  • Fakultni nemocnice v Motole
    Praha 5, 150 06, Czechia
  • IN-VIVO Sp. z o.o.
    Bydgoszcz, 85-048, Poland
  • Centrum Badań Klinicznych Jagiellońskie Centrum Innowacji sp. z o.o.
    Krakow, 30-348, Poland
  • WIP Warsaw IBD Point Profesor Kierkus
    Warszawa, 00-728, Poland
  • Szpital Bielański im. Ks. Jerzego Popiełuszki SPZOZ
    Warszawa, 01-809, Poland
  • Baskent Universitesi Dr. Turgut Noyan Adana Uygulama ve Arastirma Merkezi
    Adana, Yüreği̇r 01120, Turkey
  • Baskent Universitesi Dr. Turgut Noyan Adana Uygulama ve Arastirma Merkezi
    Adana, Yüreği̇r, Turkey
  • Baskent Universitesi Dr. Turgut Noyan Adana Uygulama ve Arastirma Merkezi
    Adana, 01120, Turkey
  • Acibadem Adana Hastanesi
    Adana, 01130, Turkey
  • Baskent Universitesi Dr. Turgut Noyan Adana Uygulama ve Arastirma Merkezi
    Adana, 01240, Turkey
  • Hacettepe Universitesi Tip Fakultesi
    Ankara, 06230, Turkey
  • Mersin Universitesi Tip Fakultesi Hastanesi
    Mersin, 33343, Turkey
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Data sharing details ↗ · www.pfizer.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2021 to primary completion in Sep 2023, 24 months.

Results were first posted in Oct 2024, 1 year 1 month after primary completion.

Of 20 phase 4 interventional studies under Anemia, Sickle Cell, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 41. This study's 24 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2021
First posted
May 20, 2021
StartActual
Aug 18, 2021
Primary completionActual
Sep 6, 2023
CompletionActual
Sep 6, 2023
Results first posted
Oct 16, 2024
Last update
Oct 16, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 16, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04893811
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
May 20, 2021
Start date
Aug 18, 2021
Primary completion
Sep 6, 2023
Completion
Sep 6, 2023
Results posted
Oct 16, 2024
Last update
Oct 16, 2024

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: MenB-FHbp vaccine · 4CMenB vaccine

Start the discussion